Foghorn Therapeutics Inc. (FHTX)
FHTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/0001628280-26-016814-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | FHTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001822462 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $30.9M |
| Net income | -$74.3M |
| Operating income | -$86.4M |
| Net margin | -240.3% |
| Operating margin | -279.5% |
| Revenue growth | +36.8% |
| Cash | $80.9M |
| Total assets | $198.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $80.3M cash; operating cash flow -$20.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 59,962,650 (2026-10-30); 56,551,289 a year earlier; 42,217,126 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $83.5M | $58.1M | -$18.2M | $80.3M | No debt tags | $112.1M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $16.1M | -$7.2M | -$17.8M | $68.1M | No debt tags | $36.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $3.3M | -$19.9M | -$25.3M | $87.7M | No debt tags | $28.2M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $9.2M | -$21.7M | -$22.3M | $80.9M | No debt tags | $30.9M | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | $8.2M | -$15.8M | -$18.9M | $89.3M | No debt tags | $24.5M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $7.6M | -$17.9M | -$21.0M | $72.6M | No debt tags | $24.2M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $6.0M | -$18.8M | -$24.0M | $61.0M | No debt tags | $23.5M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $2.9M | -$19.5M | -$24.5M | $55.5M | No debt tags | $22.6M | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-12 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 356 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.7% |
| 1 month | +11.9% |
| 3 months | -68.1% |
| Year to date | -61.7% |
| 1 year | -52.5% |
| From 52-week high | -70.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier